Immune perturbations in HIV-1–infected individuals who make broadly neutralizing antibodies

Immune perturbations in HIV-1–infected individuals who make broadly neutralizing antibodies

Induction of broadly neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development. bnAbs occur in some HIV-1–infected individuals and frequently have characteristics of autoantibodies. We have studied cohorts of HIV-1–infected individuals who made bnAbs and compared them with those who did...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Moody, M, Pedroza-Pacheco, I, Vandergrift, N, Chui, C, Lloyd, K, Parks, R, Ogbe, A, Cohen, M, Liao, H, Gao, F, McMichael, A, Montefiori, D, Verkoczy, L, Kelsoe, G, Huang, J, Shea, P, Connors, M, Borrow, P, Haynes, B
Formáid:	Journal article
Foilsithe / Cruthaithe:	American Association for the Advancement of Science 2016

Míreanna comhchosúla

Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies
de réir: Garnett Kelsoe, et al.
Foilsithe / Cruthaithe: (2013-12-01)

HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
de réir: Laurent Verkoczy, et al.
Foilsithe / Cruthaithe: (2014-05-01)

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
de réir: Haynes, BF, et al.
Foilsithe / Cruthaithe: (2022)

Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies
de réir: Borrow, P, et al.
Foilsithe / Cruthaithe: (2017)

P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody
de réir: Kelsoe G, et al.
Foilsithe / Cruthaithe: (2009-10-01)

RAB11FIP5 expression and altered natural killer cell function are associated with induction of HIV broadly neutralizing antibody responses
de réir: Bradley, T, et al.
Foilsithe / Cruthaithe: (2018)

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life.
de réir: Yates, N, et al.
Foilsithe / Cruthaithe: (2013)

Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV
de réir: Sarah B. Lloyd, et al.
Foilsithe / Cruthaithe: (2017-11-01)

Antibody lineages with evidence of somatic hypermutation persisting for >4 years in a South African subject with broad neutralizing activity
de réir: Moody M, et al.
Foilsithe / Cruthaithe: (2012-09-01)

Subordinate effect of -21M HLA-B dimorphism on NK cell repertoire diversity and function in HIV-1 infected individuals of African origin
de réir: Cubero, EM, et al.
Foilsithe / Cruthaithe: (2020)

Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.
de réir: S Gnanakaran, et al.
Foilsithe / Cruthaithe: (2010-01-01)

P04-44. Generation of antibody responses to HIV-1 membrane proximal external region (MPER) antigen
de réir: Haynes BF, et al.
Foilsithe / Cruthaithe: (2009-10-01)

Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth
de réir: Roskin, KM, et al.
Foilsithe / Cruthaithe: (2020)

Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants
de réir: David R. Martinez, et al.
Foilsithe / Cruthaithe: (2020-04-01)

Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin
de réir: Elia Moreno Cubero, et al.
Foilsithe / Cruthaithe: (2020-02-01)

Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
de réir: Yvonne Rosenberg, et al.
Foilsithe / Cruthaithe: (2015-01-01)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
de réir: Labranche, CC, et al.
Foilsithe / Cruthaithe: (2018)

Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates
de réir: Kevin O. Saunders, et al.
Foilsithe / Cruthaithe: (2017-02-01)

Autoreactivity and broad neutralization of antibodies against HIV-1 are governed by distinct mutations: Implications for vaccine design strategies
de réir: Xiaojun Li, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Lipid Binding: A Necessary Evil for Broadly Neutralizing Anti-gp41 Antibodies?
de réir: Scherer, E, et al.
Foilsithe / Cruthaithe: (2008)

Refocusing the Antibody Response: The Use of an Antibody-Masking Technique to Elicit Broadly Neutralizing Antibodies
de réir: Wan, D, et al.
Foilsithe / Cruthaithe: (2011)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
de réir: Han D, et al.
Foilsithe / Cruthaithe: (2012-09-01)

HIV-host interactions: implications for vaccine design
de réir: Haynes, B, et al.
Foilsithe / Cruthaithe: (2016)

Broadly Neutralizing Synthetic Cannabinoid Vaccines
de réir: Mingliang Lin, et al.
Foilsithe / Cruthaithe: (2020-12-01)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
de réir: Celia C LaBranche, et al.
Foilsithe / Cruthaithe: (2018-11-01)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
de réir: Celia C LaBranche, et al.
Foilsithe / Cruthaithe: (2019-03-01)

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
de réir: Kshitij Wagh, et al.
Foilsithe / Cruthaithe: (2018-03-01)

Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques.
de réir: Yvonne J Rosenberg, et al.
Foilsithe / Cruthaithe: (2016-01-01)

BCR and Endosomal TLR Signals Synergize to Increase AID Expression and Establish Central B Cell Tolerance
de réir: Masayuki Kuraoka, et al.
Foilsithe / Cruthaithe: (2017-02-01)

Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies
de réir: Rory Henderson, et al.
Foilsithe / Cruthaithe: (2019-02-01)

International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.
de réir: Daniel A Ozaki, et al.
Foilsithe / Cruthaithe: (2012-01-01)

Optimizing immunization protocols to elicit broadly neutralizing antibodies
de réir: Sprenger, Kayla G, et al.
Foilsithe / Cruthaithe: (2021)

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
de réir: LaBranche, C, et al.
Foilsithe / Cruthaithe: (2019)

Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection.
de réir: Zizhang Sheng, et al.
Foilsithe / Cruthaithe: (2016-05-01)

Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations
de réir: Wilton B. Williams, et al.
Foilsithe / Cruthaithe: (2017-11-01)

Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
de réir: Elise Landais, et al.
Foilsithe / Cruthaithe: (2018-09-01)

A Common Cellular Response to Broad Splicing Perturbations
de réir: Varineau, Jade E.
Foilsithe / Cruthaithe: (2024)

The expanding array of HIV broadly neutralizing antibodies
de réir: Laura E. McCoy
Foilsithe / Cruthaithe: (2018-10-01)

Broadly Neutralizing Antibodies for HIV-1 Prevention
de réir: Stephen R. Walsh, et al.
Foilsithe / Cruthaithe: (2021-07-01)

The potential of broadly neutralizing antibodies for HIV prevention
de réir: Huub C. Gelderblom, et al.
Foilsithe / Cruthaithe: (2024-05-01)